New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
08:10 EDTTROVTrovagene presents urine-based HPV assay clinical results
Trovagene announced that results from two independent clinical studies were presented at the 29th International Papillomavirus Conference. Results from both pilot studies consistently demonstrated that the company's urine-based assay for the detection of high-risk HPV had high sensitivity for identifying women with high grade cervical intraepithelial neoplasia. Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing. In an oral presentation entitled "Evaluation of Two Urine-Based HPV Assays In Comparison to Cervical HPV Detection and High-Grade CIN Among Women Attending a Colposcopy Clinic," results from a population-based National Cancer Institute study, conducted at the University of Oklahoma Health Sciences Center, were released. A second presentation entitled "A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women" included results from a study conducted at University of North Carolina, Chapel Hill. The company said, "The positive study results presented at the IPV Conference are very encouraging as we continue to conduct clinical studies to evaluate the performance of our urine-based high-risk HPV assay as a viable alternative to conventional HPV testing from a cervical specimen. A significantly larger, blinded study which compares sensitivity of detecting high-risk HPV in patients with CIN2/3 in urine versus cervical samples is ongoing and results will be reported by 1Q15."
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
05:16 EDTTROVTrovagene expands collaboration with Genomac
Trovagene announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring SM technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer. Prospective multi-center studies will involve leading clinical and surgical oncology centers in the Czech Republic. The first study focusing on lung cancer will enroll up to 300 patients, while the second study will enroll up to 500 patients with Stage III-IV colorectal cancer. Colorectal and lung cancer are the two most commonly occurring solid cancers in the Czech Republic.
January 20, 2015
08:18 EDTTROVTrovagene says study results support utility of cancer monitoring platform
Subscribe for More Information
January 15, 2015
07:59 EDTTROVAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 12, 2015
08:35 EDTTROVTrovagene announces clinical collaboratoin with UC San Diego
Trovagene announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the utility of detecting and monitoring EGFR mutations, using its Precision Cancer MonitoringSM platform. This large-scale study expands on the company's clinical programs in lung cancer at Memorial Sloan Kettering Cancer Center and City of Hope Medical Center.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use